Le Lézard
Classified in: Health, Science and technology
Subject: Contract/Agreement

Medidata and Mapi Research Trust (MRT) Announce Strategic Collaboration to Standardize eCOA Global Library of Questionnaires

Medidata (NASDAQ: MDSO) and Mapi Research Trust today announced a new critical mission: to build a digital, global library of pre-configured and pre-approved eCOA (clinical outcomes assessment) questionnaires. The collaboration will create reusable versions of MRT distributed questionnaires in Medidata Rave eCOA, collecting COA data from hundreds of studies each year on the Medidata platform.

"This new collaboration with MRT will seek to solve two major eCOA implementation struggles that affect the pharmaceutical industry - the rework involved in building the same questionnaire in multiple studies for different sponsors, and the timelines required for deploying translated versions across global trials," said Glen de Vries, president, co-founder, Medidata. "MRT's licensing and author relationships, combined with Medidata's expertise and eCOA solution, will drive significant efficiencies in study management, empowering sponsors to create more patient-centric clinical trials."

The collaboration will allow Medidata and MRT to engage with instrument authors and study sponsors, resulting in questionnaires that are pre-approved, translated for global implementations, and archived for future use. Based on this innovative approach, the comprehensive new eCOA library will include:

"Industry timelines from kick-off to go-live for eCOA studies have long been stuck at 12 to 16 weeks, because of repeated efforts rebuilding the same forms and translations over and over for different studies," says Katrin Conway, Managing Director of Mapi Research Trust. "The Medidata and MRT global eCOA Library seeks to cut these timelines by as much as 50-60% by building a library of pre-approved questionnaires that Medidata customers on the Rave platform of products can use."

About Medidata

Medidata is leading the digital transformation of life sciences, with the world's most-used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by industry experts, Medidata helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata and its companies, Acorn AI and SHYFT, serve more than 1,300 customers and partners worldwide and empower more than 150,000 certified users every day to create hope for millions of patients. Discover the future of life science: www.medidata.com

About Mapi Research Trust:

Mapi Research Trust was created as a non-profit arm of Mapi Group which was acquired by ICON plc in 2017, creating the world's second largest provider of late phase services. Mapi Research Trust works in collaboration with academic researchers, life-science companies and regulatory bodies to support the industry in reducing the burden of implementing COA in Health research. It is the largest curator of Clinical Outcomes Assessments (COA) and their translations, the largest single COA licensing provider and the most trusted name in distribution of COA instruments representing over 350 exclusive questionnaires. Visit http://mapi-trust.org/ for more information.

These press releases may also interest you

at 01:05
Sartorius, a leading international partner of biopharmaceutical research and the industry, performed dynamically in the third quarter as well, achieving double-digit growth rates in sales revenue, order intake and earnings in the first nine months....

at 01:05
Today, leading cryptocurrency exchange bitFlyer has announced the launch of the bitFlyer app across Europe and the USA. The app, available for free on both iOS and Android, will allow users to buy and sell Bitcoin (BTC), Ethereum (ETH), Litecoin...

at 01:05
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced results from a retrospective chart review study (EVOLVE), which investigated the likelihood of serious adverse events and serious infections with vedolizumab and...

at 01:05
Sartorius, a leading partner to the biopharmaceutical industry and laboratories, has signed an agreement to acquire parts of Danaher's Life Science portfolio for approximately $750 million in cash. The businesses had combined sales turnover of...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave150 study, evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable...

at 01:01
New Cloud Bookings Up 39%, Software License Revenue Down 1%  Cloud Revenue Up 37%  Cloud Gross Margin Up More Than 5 Percentage Points IFRS Operating Profit Up 36%; Non-IFRS Operating Profit Up 20%  IFRS Operating Margin Up 4.2pp; Non-IFRS Operating...

News published on 12 september 2019 at 08:35 and distributed by: